Muhammad Wasif Saif

Summary

Affiliation: Yale University
Country: USA

Publications

  1. pmc Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma
    Walid Shaib
    Hospital of Saint Raphael, New Haven, Connecticut, USA
    Yale J Biol Med 83:27-33. 2010
  2. pmc Aggressive Burkitt-like lymphoma of colon in a patient with prior celiac disease
    M Ahluwalia
    Hematology and Oncology, Brooklyn Hospital Center, Brooklyn, New York, USA
    Yale J Biol Med 79:173-5. 2006
  3. pmc Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature
    Mitesh J Borad
    Translational Genomics Research Institute, Scottsdale Clinical Research Institute, AZ, USA
    Yale J Biol Med 82:1-6. 2009
  4. pmc Targeting cancers in the gastrointestinal tract: role of capecitabine
    Muhammad Wasif Saif
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    Onco Targets Ther 2:29-41. 2009
  5. ncbi request reprint Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival
    Muhammad Wasif Saif
    Yale University School of Medicine, Yale Cancer Center, Section of Medical Oncology, 333 Cedar Street FMP 116, New Haven, CT 06520, USA
    Expert Opin Drug Saf 8:507-14. 2009
  6. pmc Management of ascites due to gastrointestinal malignancy
    Muhammad W Saif
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA
    Ann Saudi Med 29:369-77. 2009
  7. ncbi request reprint Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010
    Scott Bussom
    Pharmacology Department, Yale University School of Medicine, New Haven, CT, USA
    JOP 11:128-30. 2010
  8. ncbi request reprint Management of hypomagnesemia in cancer patients receiving chemotherapy
    Muhammad Wasif Saif
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA
    J Support Oncol 6:243-8. 2008
  9. ncbi request reprint Erlotinib: the first biologic in the management of pancreatic cancer
    M Wasif Saif
    Yale University School of Medicine, New Haven, CT, USA
    Expert Opin Pharmacother 9:1595-607. 2008
  10. ncbi request reprint Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients
    Muhammad Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
    JOP 9:267-74. 2008

Collaborators

Detail Information

Publications116 found, 100 shown here

  1. pmc Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma
    Walid Shaib
    Hospital of Saint Raphael, New Haven, Connecticut, USA
    Yale J Biol Med 83:27-33. 2010
    ....
  2. pmc Aggressive Burkitt-like lymphoma of colon in a patient with prior celiac disease
    M Ahluwalia
    Hematology and Oncology, Brooklyn Hospital Center, Brooklyn, New York, USA
    Yale J Biol Med 79:173-5. 2006
    ..Recent large retrospective studies confirm that celiac disease significantly increases risk of developing small bowel lymphomas by 30 to 40 percent and other gut malignancies by 83-fold...
  3. pmc Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature
    Mitesh J Borad
    Translational Genomics Research Institute, Scottsdale Clinical Research Institute, AZ, USA
    Yale J Biol Med 82:1-6. 2009
    ..As such, it is anticipated that previously uncommon occurrences such as skeletal metastases will become more frequent...
  4. pmc Targeting cancers in the gastrointestinal tract: role of capecitabine
    Muhammad Wasif Saif
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    Onco Targets Ther 2:29-41. 2009
    ..The author summarizes the current data on the role of capecitabine in the management of gastrointestinal cancers...
  5. ncbi request reprint Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival
    Muhammad Wasif Saif
    Yale University School of Medicine, Yale Cancer Center, Section of Medical Oncology, 333 Cedar Street FMP 116, New Haven, CT 06520, USA
    Expert Opin Drug Saf 8:507-14. 2009
    ..This is the first human study that analyzes the association of TP/DPD ratio with overall survival and disease-free survival in cases of locally advanced pancreatic cancer (LAPC)...
  6. pmc Management of ascites due to gastrointestinal malignancy
    Muhammad W Saif
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA
    Ann Saudi Med 29:369-77. 2009
    ..Median survival after diagnosis of malignant ascites is in the range of 1 to 4 months; survival is apt to be longer for ovarian and breast cancers if systemic anti-cancer treatments are available...
  7. ncbi request reprint Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010
    Scott Bussom
    Pharmacology Department, Yale University School of Medicine, New Haven, CT, USA
    JOP 11:128-30. 2010
    ..Herein, the authors report some updated information from the 2010 ASCO Gastrointestinal Cancers Symposium in detecting early stage pancreatic cancer...
  8. ncbi request reprint Management of hypomagnesemia in cancer patients receiving chemotherapy
    Muhammad Wasif Saif
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA
    J Support Oncol 6:243-8. 2008
  9. ncbi request reprint Erlotinib: the first biologic in the management of pancreatic cancer
    M Wasif Saif
    Yale University School of Medicine, New Haven, CT, USA
    Expert Opin Pharmacother 9:1595-607. 2008
    ..The EGFR is known to be overexpressed in pancreatic cancer and data suggest that the presence of EGFR is associated with a poor prognosis...
  10. ncbi request reprint Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients
    Muhammad Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
    JOP 9:267-74. 2008
    ..Adequate and timely management of rash depending on the grade of rash is important for therapy continuation...
  11. doi request reprint Capecitabine: an overview of the side effects and their management
    Muhammad Wasif Saif
    Medical Oncology, Yale University School of Medicine, Section of Medical Oncology, New Haven, Connecticut 06520, USA
    Anticancer Drugs 19:447-64. 2008
    ....
  12. ncbi request reprint Erlotinib-induced acute hepatitis in a patient with pancreatic cancer
    Muhammad Wasif Saif
    Medical Oncology and Developmental Therapeutics Program, Yale University School of Medicine, New Haven, CT 06510, USA
    Clin Adv Hematol Oncol 6:191-199. 2008
  13. ncbi request reprint Intraductal papillary mucinous neoplasia (IPMN). Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010
    Scott Bussom
    Pharmacology Department, Yale University School of Medicine, New Haven, CT, USA
    JOP 11:131-4. 2010
    ..Future studies will hopefully provide insight into the many unanswered questions...
  14. pmc Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer
    Muhammad Wasif Saif
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06519, United States
    World J Gastroenterol 15:3855-64. 2009
    ..Secondary resection is a valid treatment goal for certain patients with initially unresectable liver metastases and an important end point for future clinical trials...
  15. pmc Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States
    Muhammad Wasif Saif
    Gastrointestinal Cancers Program, Yale Medical Oncology, New Haven, CT 06519, United States
    World J Gastroenterol 15:4415-22. 2009
    ..To assess the use of capecitabine-based therapy and associated complication rates in patients with gastroesophageal cancer (GEC) in a real-world treatment setting...
  16. ncbi request reprint Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008
    Muhammad Wasif Saif
    Yale Cancer Center, Yale University School of Medicine New Haven, CT, USA
    JOP 9:91-8. 2008
    ..We, as oncologist, have to change our attitudes towards clinical trials and need to think beyond a trial design such as gemcitabine vs. drug of our choice...
  17. ncbi request reprint Capecitabine-related cardiotoxicity: recognition and management
    Muhammad Wasif Saif
    Yale University School of Medicine, Section of Medical Oncology, New Haven, CT 06520, USA
    J Support Oncol 6:41-8. 2008
  18. ncbi request reprint Chemotherapy options and outcomes in older adult patients with colorectal cancer
    Muhammad W Saif
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA
    Crit Rev Oncol Hematol 72:155-69. 2009
    ..In this review, we will evaluate the chemotherapy regimens investigated in older adult patients with CRC, and how the safety profiles and efficacy of chemotherapy in the older adult compare with those observed in younger patients...
  19. ncbi request reprint Safety of capecitabine use in patients with liver dysfunction
    Muhammad Wasif Saif
    Yale University School of Medicine, Yale New Haven Hospital, New Haven, CT 06510, USA
    Clin Adv Hematol Oncol 5:730-2; discussion 736. 2007
  20. ncbi request reprint New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008
    Muhammad Wasif Saif
    Medical Oncology, Yale University School of Medicine New Haven, CT, USA
    JOP 9:391-7. 2008
    ..CONKO-003 study: final results of a randomized trial in patients with gemcitabine-refractory pancreatic cancer...
  21. ncbi request reprint Translational research in pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008
    Muhammad Wasif Saif
    Medical Oncology, Yale University School of Medicine New Haven, CT, USA
    JOP 9:398-402. 2008
    ..Pancreatic cancer remains a dismal disease and early diagnostic markers and therapeutic targets are urgently needed...
  22. doi request reprint Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas
    Muhammad Wasif Saif
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    Cancer J 15:339-43. 2009
    ..A phase I study proved that the combination (gemcitabine plus LY) is safe and well tolerated...
  23. ncbi request reprint Oxaliplatin-induced hyperexcitability syndrome in a patient with pancreatic cancer
    Hamid Saadati
    Yale Cancer Center New Haven, CT, USA
    JOP 10:459-61. 2009
    ..Future studies will be needed to confirm this as well as to determine the long-term adverse effects associated with pregabalin...
  24. ncbi request reprint Thrombotic microangiopathy associated with gemcitabine: rare but real
    M Wasif Saif
    Associate Professor Yale University, Yale Cancer Center, Department of Medical Oncology, CT, 333 Cedar Street, FMP 116 New Haven, CT 06520, USA
    Expert Opin Drug Saf 8:257-60. 2009
    ..The most effective treatment is discontinuation of gemcitabine, the provision of antihypertensive medications as needed, and consideration of plasmapheresis or use of immunoadsorption column in severe cases...
  25. ncbi request reprint Staphylococcus aureus Bacteremia Related with Erlotinib Skin Toxicity in a Patient with Pancreatic Cancer
    Jia Li
    Yale Cancer Center New Haven, CT, USA
    JOP 10:338-40. 2009
    ..Monitor patients closely after starting EGFR blocking agents and initiate immediate skin care based on general guideline are highly recommended...
  26. doi request reprint Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer
    Muhammad Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA
    Cancer Chemother Pharmacol 65:107-12. 2009
    ..in Cancer Chemother Pharmacol 63(6):1017-1022, 2009). However, safety of cetuximab after IR with panitumumab is not known. We report two patients successfully desensitized with cetuximab after IR with panitumumab...
  27. doi request reprint Erlotinib-induced trichomegaly in a male patient with pancreatic cancer
    Muhammad Wasif Saif
    Gastrointestinal Cancers Program, Yale Cancer Center, and Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cutan Ocul Toxicol 29:62-6. 2010
    ..Previous reported cases all involved female lung cancer patients. We emphasize the importance of recognizing the side effects of EGFR inhibitor therapy and its implications on the prognosis of the cancer treated...
  28. doi request reprint Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes
    M Wasif Saif
    Developmental Therapeutics Program, Yale Cancer Center, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Natl Cancer Inst 101:1543-52. 2009
    ..We review the data on pharmacokinetically guided dose adjustment of 5-FU and discuss the potential of this approach to advance therapeutic outcomes...
  29. ncbi request reprint Fluoropyrimidine-associated cardiotoxicity: revisited
    M Wasif Saif
    Yale University School of Medicine, FMP 116, CT 06520, New Haven, USA
    Expert Opin Drug Saf 8:191-202. 2009
    ..The syndrome of 5-fluorouracil (5-FU)-associated cardiotoxicity remains poorly defined...
  30. doi request reprint Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer
    Muhammad W Saif
    Yale University School of Medicine, New Haven, CT 06520 8032, USA
    Cancer Invest 28:186-94. 2010
    ..To determine in patients, with locally advanced or metastatic pancreatic cancer (APC), efficacy and safety of treatment with intravenous paclitaxel loaded polymeric micelle (GPM)...
  31. ncbi request reprint K-ras mutations in colorectal cancer: a practice changing discovery
    M Wasif Saif
    Gastroinestinal Cancers Program, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Adv Hematol Oncol 7:45-53, 64. 2009
    ..Further confirmatory prospective studies are needed to evaluate the role of K-Ras mutation detections in tumor metastases, early stage CRC, and method of sampling specimens...
  32. ncbi request reprint S-1: a promising new oral fluoropyrimidine derivative
    Muhammad Wasif Saif
    Yale University School of Medicine, Division of Medical Oncology, 333 Cedar Street, FMP 116 New Haven, CT 06520, USA
    Expert Opin Investig Drugs 18:335-48. 2009
    ..The authors review the current literature and provide their expert opinion on the incorporation of S-1 in the treatment of solid malignancies [corrected]...
  33. doi request reprint Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies
    M Wasif Saif
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar Street, FMP 116 New Haven, CT 06520, USA
    Phytomedicine 17:161-9. 2010
    ..We conducted a Phase I study using PHY906 in combination with capecitabine in patients with advanced pancreatic and gastrointestinal malignancies to determine the maximum tolerated dose (MTD) of capecitabine in combination with PHY906...
  34. doi request reprint Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature
    Muhammad Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA
    Cancer Chemother Pharmacol 63:1017-22. 2009
    ..Safety of panitumumab in patients with a previous severe HSR with cetuximab is not fully known. We present three patients with GI cancers who tolerated panitumumab without HSR after experiencing severe HSR to cetuximab...
  35. doi request reprint Colorectal cancer in review: the role of the EGFR pathway
    Muhammad W Saif
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA
    Expert Opin Investig Drugs 19:357-69. 2010
    ..An increased understanding of the EGFR pathway in CRC has paved the way for the development of other targeted agents to augment therapeutic efficacy as well as for efforts to circumvent tumor resistance to therapy...
  36. doi request reprint Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?
    Muhammad Wasif Saif
    Yale University School of Medicine, New Haven, Connecticut, USA
    Cutan Ocul Toxicol 27:311-5. 2008
    ..This case also suggests that severe toxicity to infusional 5-FU might not be indicative of severe toxicity to oral fluoropyrimidine drugs...
  37. ncbi request reprint Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review
    M W Saif
    Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA
    Int J Colorectal Dis 23:139-45. 2008
    ..There is no randomized trial comparing infusional 5-FU to capecitabine. We retrospectively compared the safety and efficacy of CAP-based regimens with well-established CIV-5-FU-based regimens in LARC...
  38. ncbi request reprint Anti-angiogenesis therapy in pancreatic carcinoma
    Muhammad Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
    JOP 7:163-73. 2006
    ..Role of markers of angiogenesis in predicting response to therapy is also discussed...
  39. ncbi request reprint Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine
    Muhammad Wasif Saif
    Yale Cancer Center, New Haven, CT, USA
    Clin Colorectal Cancer 6:219-23. 2006
    ..In addition to severe to life-threatening toxicities akin to 5-fluorouracil, capecitabine can lead to unusual variants of common toxicities, including HFS, in DPD-deficient patients...
  40. ncbi request reprint Role of panitumumab in the management of metastatic colorectal cancer
    Mohammad Wasif Saif
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Colorectal Cancer 6:118-24. 2006
    ..Recent progress in development of panitumumab in the management of CRC is reviewed, and management of associated rash is discussed herein...
  41. ncbi request reprint Hypersensitivity reactions associated with oxaliplatin
    M Wasif Saif
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA
    Expert Opin Drug Saf 5:687-94. 2006
    ..In this article, the author discusses the incidence, clinical presentation, pathogenesis, risk factors and current strategies of management of HSR associated with oxaliplatin...
  42. ncbi request reprint Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006
    Muhammad Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine New Haven, CT 06520, USA
    JOP 7:337-48. 2006
    ..drug of our choice. Environment within which research is being conducted also has to be changed and last but not the least, access to trials for patients with pancreatic cancer is the key step in the fight against pancreatic cancer...
  43. ncbi request reprint Targeted agents for adjuvant therapy of colon cancer
    Mohammad Wasif Saif
    Yale Cancer Center, New Haven, CT 06520, USA
    Clin Colorectal Cancer 6:46-51. 2006
    ..This article reviews the adjuvant therapy for colon cancer and discusses the potential role and current trials involving the targeted agents...
  44. ncbi request reprint Incidence and management of bevacizumab-related toxicities in colorectal cancer
    M Wasif Saif
    Yale University School of Medicine, Division of Medical Oncology, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA
    Expert Opin Drug Saf 5:553-66. 2006
    ..This review addresses the toxicities noted in trials using bevacizumab for the treatment of CRC and provides recommendations for toxicity management...
  45. ncbi request reprint Primary pancreatic lymphomas
    Muhammad Wasif Saif
    Yale University School of Medicine, New Haven, CT 06520, USA
    JOP 7:262-73. 2006
    ..Treatment usually consists of a combination of chemotherapy and radiation therapy, or stem cell transplantation. Primary pancreatic lymphomas has a much better prognosis than adenocarcinoma of the pancreas...
  46. ncbi request reprint Biology of colorectal cancer
    Muhammad Wasif Saif
    From the Section of Medical Oncology and Developmental Therapeutics Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Cancer J 16:196-201. 2010
    ..These targeted therapies can then be used alone or in combination with standard cytotoxic chemotherapy regimens...
  47. pmc A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors
    Muhammad Wasif Saif
    Yale Medical Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Anticancer Drugs 21:716-23. 2010
    ..The administration of edotecarin in combination with infusional 5-FU/LV once every 14 days, even without the 5-FU bolus, did not permit adequate time for recovery from neutropenia...
  48. ncbi request reprint Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
    M Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Colorectal Cancer 5:359-62. 2006
    ..Screening should be considered in view of the widespread use of capecitabine and 5-FU, the severe toxicity that can develop in patients with low DPD activity, and the prevalence of the mutation...
  49. pmc Role and cost effectiveness of PET/CT in management of patients with cancer
    Muhammad Wasif Saif
    Yale University School of Medicine, Section of Medical Oncology, New Haven, Connecticut 06520, USA
    Yale J Biol Med 83:53-65. 2010
    ..The authors review the literature on the role of PET/CT in management of various tumors and discuss the medicoeconomic usefulness...
  50. ncbi request reprint Peripheral neuropathy exacerbation associated with topical 5-fluorouracil
    Muhammad Wasif Saif
    Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Anticancer Drugs 17:1095-8. 2006
    ....
  51. ncbi request reprint Management of colorectal cancer in pregnancy: a multimodality approach
    M Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA
    Clin Colorectal Cancer 5:247-56. 2005
    ..Herein, the author reviews the literature concerning the diagnosis and treatment of CRC in pregnancy and discusses the role of newer agents approved for the treatment of CRC...
  52. ncbi request reprint Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison
    M Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine, 333 Cedar St, FMP 116, New Haven, CT 06520, USA
    Clin Colorectal Cancer 5:89-100. 2005
    ..Capecitabine offers physicians a more convenient treatment for advanced colorectal cancer, with manageable toxicity and antitumor activity comparable to that of CI therapies...
  53. ncbi request reprint Gemcitabine-related radiation recall in a patient with pancreatic cancer
    M Wasif Saif
    Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Anticancer Drugs 17:107-11. 2006
    ..We suggest discontinuing gemcitabine if radiation recall is observed. Further studies are warranted into the pathogenesis of this unique phenomenon...
  54. ncbi request reprint Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome
    M Wasif Saif
    Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, USA
    J Clin Oncol 23:8679-87. 2005
    ....
  55. ncbi request reprint Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma
    Muhammad Wasif Saif
    Developmental Therapeutics Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Colorectal Cancer 6:229-34. 2006
  56. ncbi request reprint Pancreatoblastoma
    Muhammad Wasif Saif
    Yale University School of Medicine, New Haven, CT 06520, USA
    JOP 8:55-63. 2007
    ..Awareness of this rare tumor of pancreas is essential for early detection and proper management. The author review the clinical presentation, etiology, diagnosis, treatment and prognosis of PB in this presentation...
  57. ncbi request reprint Genetic alterations in pancreatic cancer
    Muhammad Wasif Saif
    Yale University School of Medicine, Section of Medical Oncology, New Haven, CT 06520, USA
    World J Gastroenterol 13:4423-30. 2007
    ..This review focuses on medical research on pancreatic cancer models and the underlying genetic alterations...
  58. ncbi request reprint Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer
    M Wasif Saif
    Division of Medical Onclogy, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Colorectal Cancer 7:144-8. 2008
    ..To our knowledge, this case report is the second report of possible correlation between rash and a positive drug response associated with bevacizumab and warrants further investigation of similar observation...
  59. ncbi request reprint The clinical significance of autoantibodies in gastrointestinal malignancies: an overview
    Muhammad Wasif Saif
    Yale University School of Medicine, Division of Medical Oncology, 333 Cedar Street, FMP 116, New Haven, CT 06520 8032, USA
    Expert Opin Biol Ther 7:493-507. 2007
    ..The authors review the autoantibodies associated with gastrointestinal malignancies and their clinical implications...
  60. ncbi request reprint Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase
    Muhammad Wasif Saif
    Departments of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
    Cancer J 13:247-56. 2007
    ....
  61. ncbi request reprint Secondary pancreatic involvement by a diffuse large B-cell lymphoma presenting as acute pancreatitis
    M Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, FMP 116, New Haven, CT 06520, United States
    World J Gastroenterol 13:4909-11. 2007
    ..Our case appears to be the second report of such a manifestation. Both cases responded well to chemotherapy...
  62. ncbi request reprint Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer
    Muhammad Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
    Cancer Chemother Pharmacol 61:349-54. 2008
    ..We present a case of hyperexcitability syndrome that developed during the treatment of pancreatic cancer with oxaliplatin and gemcitabine (GEMOX) that was successfully treated with pregabalin...
  63. ncbi request reprint Management of skin toxicities of anti-EGFR agents in patients with pancreatic cancer and other GI tumors by using electronic communication: effective and convenient
    Muhammad Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
    JOP 11:176-82. 2010
    ..We suggest that electronic communication is of crucial importance to detect early, diagnose and treat anti-EGFR related skin rash in order to continue the benefit of anti-EGFR...
  64. pmc Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction
    M Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
    World J Gastroenterol 13:5277-81. 2007
    ....
  65. ncbi request reprint A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors
    Muhammad Wasif Saif
    Department of Medicine, Section of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA
    Cancer Chemother Pharmacol 60:871-82. 2007
    ..To determine the maximal tolerated doses (MTD) and dose-limiting toxicities (DLT) of combination of 24-h infusions of gemcitabine and irinotecan in patients with advanced solid tumors...
  66. ncbi request reprint Gastrointestinal perforation due to bevacizumab in colorectal cancer
    Muhammad Wasif Saif
    Yale Cancer Center, Yale University School of Medicine, Divisions of Medical and Surgical Oncology, 333 Cedar Street, FMP 116, New Haven, Connecticut 06520, USA
    Ann Surg Oncol 14:1860-9. 2007
    ..This article reviews the incidence, presentation, pathogenesis, risk factors, and management of GI perforation in patients with colorectal cancer who are treated with bevacizumab...
  67. ncbi request reprint Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer
    Muhammad Wasif Saif
    Division of Hematology Oncology, Department of Medicine, University of Alabama at Birmingham, 35294 3300, USA
    JOP 6:325-33. 2005
    ..Capecitabine is currently being evaluated for the treatment of a variety of gastrointestinal malignancies...
  68. ncbi request reprint 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice
    Muhammad Wasif Saif
    University of Alabama at Birmingham, USA
    Cancer Chemother Pharmacol 58:136-42. 2006
    ..PN401 may therefore be useful for permitting dose escalation of 5-fluorouracil (5-FU) with consequent improvements in antitumor efficacy...
  69. ncbi request reprint Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate
    Stephen H Wrzesinski
    Yale New Haven Hospital and Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Anticancer Drugs 18:721-4. 2007
    ....
  70. ncbi request reprint Any second-line therapy for advanced pancreatic cancer? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010
    Jia Li
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    JOP 11:151-3. 2010
    ..Among single agents, erlotinib and Src inhibitor failed to show seemingly benefit, while abraxane and pemetrexed deserve further investigation...
  71. ncbi request reprint Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer
    Walid Shaib
    Hospital of Saint Raphael, Yale University School of Medicine, New Haven, CT 06521, USA
    JOP 9:708-14. 2008
    ..The most common side effect is myelosuppression. Dyspnea is reported in 23% and bronchospasm occurs in less than 2% of subjects. Acute respiratory distress syndrome is rare with single agent use or in combination...
  72. ncbi request reprint Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
    Armin Shahrokni
    Yale University School of Medicine, New Haven, CT, USA
    Clin Colorectal Cancer 8:231-4. 2009
    ..Genetic variations such as polymorphic abnormality of TYMS are potential causative factors for a significant portion of serious adverse reactions to 5-FU-based therapy...
  73. ncbi request reprint Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009
    Jia Li
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    JOP 10:361-5. 2009
    ..Thinking beyond the gemcitabine box and exploring novel agents are very crucial now...
  74. ncbi request reprint Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma
    Yun Yen
    Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010 3000, USA
    Anticancer Res 29:4083-92. 2009
    ..2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population...
  75. ncbi request reprint Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity
    Walid Shaib
    Hospital of Saint Raphael, New Haven, CT, USA
    In Vivo 23:821-6. 2009
    ..In conclusion, Bolus 5-FU can be used in patients developing cardio-toxicity due to 5-FU infusion...
  76. ncbi request reprint Impact of ethnicity on outcome in pancreatic carcinoma
    Muhammad Wasif Saif
    University of Alabama at Birmingham, Birmingham, AL 35294 3300, USA
    JOP 6:246-54. 2005
    ..Ethnicity is an important factor known to impact the biology and outcome of many cancers. In pancreatic cancer, African Americans are thought to have a higher incidence and poorer prognosis than Whites...
  77. ncbi request reprint Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010
    Joshua Richter
    Yale University School of Medicine, New Haven, CT 06536 0740, USA
    JOP 11:144-7. 2010
    ..The authors summarize these findings presented at the 2010 ASCO Gastrointestinal Cancers Symposium, January 22-24, 2010, Orlando, FL, USA...
  78. ncbi request reprint Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010
    Joshua Richter
    Yale University School of Medicine, New Haven, CT 06536 0740, USA
    JOP 11:139-43. 2010
    ..The authors summarize and discuss the data from the meeting...
  79. ncbi request reprint Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010
    Christina Brus
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    JOP 11:321-3. 2010
    ..These abstracts provide exciting new directions for the treatment of gemcitabine-refractory advanced pancreatic cancer...
  80. ncbi request reprint Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer
    Susan Alsamarai
    Yale University School of Medicine New Haven, CT, USA
    JOP 9:185-91. 2008
    ..The early phase II study demonstrated a response rate approaching 20% while the combination is reaching more than 35%...
  81. ncbi request reprint Therapeutic tools in pancreatic cancer
    Christopher J Hoimes
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    JOP 10:118-22. 2009
    ..Validated clinical tools that can assist in managing patients through the narrow therapeutic window are needed...
  82. ncbi request reprint Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study
    Muhammad Wasif Saif
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar Street FMP 116, New Haven, CT 06520, USA
    Anticancer Res 30:2905-9. 2010
    ..Docetaxel activity against pancreatic cancer is reported both in the preclinical and clinical setting. This study retrospectively evaluated the role of docetaxel as second-line therapy in patients with gemcitabine-refractory disease...
  83. ncbi request reprint The first-line treatment for advanced pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010
    Man Yee Merl
    Yale New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA
    JOP 11:148-50. 2010
    ..In this article, we review and summarize the findings from these studies...
  84. ncbi request reprint Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010
    Jia Li
    Yale University School of Medicine, New Haven, CT, USA
    JOP 11:310-2. 2010
    ..Abstract e14625 combined S-1 to gemcitabine and abstract #4113 demonstrated a positive correlation between symptoms and CA 19-9 levels with the length of survival...
  85. ncbi request reprint Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy
    Muhammad Wasif Saif
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar Street FMP 116, New Haven, CT 06520, USA
    Anticancer Res 30:2927-33. 2010
    ..Oxaliplatin use in gastrointestinal malignancies is limited by neurotoxicity. This study aimed to assess the efficacy of pregabalin (LYRICA(R)) in the treatment of oxaliplatin-induced neurotoxicity...
  86. ncbi request reprint Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies
    Muhammad Wasif Saif
    Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520 8032, USA
    Oncology (Williston Park) 20:11-9. 2006
    ..In this article we review various treatment options, including cytotoxic and targeted agents, currently available for patients with mCRC...
  87. ncbi request reprint Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase
    Muhammad Wasif Saif
    Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA
    Cancer Chemother Pharmacol 58:771-5. 2006
    ..We report here another pancreatic cancer patient with a radiation recall receiving capecitabine following capecitabine-XRT...
  88. ncbi request reprint Pancreatic cancer: are we moving forward yet? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 20th, 2007
    Muhammad Wasif Saif
    Yale University School of Medicine, Section of Medical Oncology, New Haven, CT 06520, USA
    JOP 8:166-76. 2007
    ....
  89. ncbi request reprint Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?
    Kyle T Elligers
    Yale University School of Medicine New Haven, CT, USA
    JOP 9:197-202. 2008
    ....
  90. ncbi request reprint 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients
    Muhammad Wasif Saif
    Yale University School of Medicine, New Haven, CT 06520, USA
    J Gastrointestin Liver Dis 17:173-8. 2008
    ..Often, there are liver lesions seen on diagnostic CT suspicious for secondary deposits. Positron emission tomography (PET)-CT may have a great potential in confirming or ruling out actual malignancy in those areas...
  91. ncbi request reprint Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008
    Muhammad Wasif Saif
    Medical Oncology, Yale University School of Medicine New Haven, CT, USA
    JOP 9:403-7. 2008
    ..This article provides a summary of herbal medicine, presented at the Annual Meeting of ASCO, 2008. The clinical applications of these active compounds warrant further investigation in randomized, controlled clinical trials...
  92. ncbi request reprint Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009
    Muhammad Wasif Saif
    Yale University School of Medicine, New Haven, CT 06520, USA
    JOP 10:373-7. 2009
    ....
  93. ncbi request reprint Platelet count less than SHARP: what does a case series reveal?
    M Wasif Saif
    Expert Opin Drug Saf 9:1-8. 2010
    ....
  94. ncbi request reprint Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects
    Carmelo Blanquicett
    Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294 3300, USA
    Clin Cancer Res 11:8773-81. 2005
    ..This chemoradiation regimen was chosen based on our molecular analysis of pancreatic adenocarcinoma...
  95. ncbi request reprint Colon cancer in pregnancy
    Alex Minter
    University of Alabama at Birmingham, USA
    Cancer Control 12:196-202. 2005
  96. doi request reprint Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512)
    My Merl
    Yale University School of Medicine, Yale Cancer Centre, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA
    Expert Opin Investig Drugs 18:1257-64. 2009
    ..The objective of this review is to evaluate the literature for evidence of efficacy and safety of fluoropyrimidine plus gemcitabine (FG) in patients with advanced CRC...
  97. ncbi request reprint A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin
    Heather R Shah
    University of Alabama at Birmingham, AL, USA
    Clin Colorectal Cancer 5:354-8. 2006
    ..The extent and complications of the interaction between capecitabine and warfarin are not fully known...